FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Deininger

Research Profile

Disorders

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Chemicals & Drugs

Physiology

Genes & Molecular Sequences

Genes, abl

Concepts & Ideas

Living Beings

Mouse

Anatomy

Procedures

Phenomena

Phosphorylation

Co-author Network

Publications

TOP 3
Julia E Maxson; Shannon McWeeney; Stephen T Oh; Daniel A Pollyea; J Blake Pond; Cristina E Tognon; Beth Wilmot; Anupriya Agarwal; Daniel Bottomly; Bill H Chang; Robert H Collins; Michael W N Deininger; Brian J Druker; Christopher A Eide; Angela G Fleischman; Jason Gotlib; Basem Goueli; Marc Loriaux; Jeffrey W Tyner
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
Jamshid Sorouri Khorashad; Ira L Kraft; Thoralf Lange; David Marin; Clinton C Mason; Thomas O'Hare; Anthony D Pomicter; Alistair G Reid; Simona Soverini; Philippe Szankasi; Matthew S Zabriskie; Lauren T Adrian; Mary Alikian; David J Anderson; Brian J Druker; Christopher A Eide; Anna Eiring; Johanna C Estrada; Letizia Foroni; Zhimin Gu; Todd W Kelley; Michael W N Deininger
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Jorge E Cortes; Michael W N Deininger; Brian J Druker; Ian W Flinn; Frank G Haluska; Simin Hu; Hagop Kantarjian; Michael J Mauro; Narayana I Narasimhan; Thomas O'Hare; Victor M Rivera; Neil P Shah; Dale Bixby; Tim Clackson; Christopher D Turner; Moshe Talpaz
Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Deininger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Julia E Maxson; Shannon McWeeney; Stephen T Oh; Daniel A Pollyea; J Blake Pond; Cristina E Tognon; Beth Wilmot; Anupriya Agarwal; Daniel Bottomly; Bill H Chang; Robert H Collins; Michael W N Deininger; Brian J Druker; Christopher A Eide; Angela G Fleischman; Jason Gotlib; Basem Goueli; Marc Loriaux; Jeffrey W Tyner
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
The New England journal of medicine 2013;368(19):1781-90.
2013: Jamshid Sorouri Khorashad; Ira L Kraft; Thoralf Lange; David Marin; Clinton C Mason; Thomas O'Hare; Anthony D Pomicter; Alistair G Reid; Simona Soverini; Philippe Szankasi; Matthew S Zabriskie; Lauren T Adrian; Mary Alikian; David J Anderson; Brian J Druker; Christopher A Eide; Anna Eiring; Johanna C Estrada; Letizia Foroni; Zhimin Gu; Todd W Kelley; Michael W N Deininger
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Blood 2013;121(3):489-98.
2012: Jorge E Cortes; Michael W N Deininger; Brian J Druker; Ian W Flinn; Frank G Haluska; Simin Hu; Hagop Kantarjian; Michael J Mauro; Narayana I Narasimhan; Thomas O'Hare; Victor M Rivera; Neil P Shah; Dale Bixby; Tim Clackson; Christopher D Turner; Moshe Talpaz
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
The New England journal of medicine 2012;367(22):2075-88.
2012: E Traer; A Agarwal; Brian J Druker; A M Eiring; R MacKenzie; Thomas O'Hare; J Snead; Michael W N Deininger
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.
Leukemia 2012;26(5):1140-3.
2011: Thomas O'Hare; Richard D Press; Victor M Rivera; Julie Toplin; Stephane Wong; Fei Yang; Huihong You; Matthew S Zabriskie; Lauren T Adrian; Anupriya Agarwal; Amie S Corbin; Michael W N Deininger; Christopher A Eide; Brian J Druker
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Blood 2011;118(19):5250-4.
2011: Jamshid Sorouri Khorashad; Michael W N Deininger
Selection of therapy: rational decisions based on molecular events.
Hematology/oncology clinics of North America 2011;25(5):1009-23, vi.
2011: Christopher A Eide; Lauren T Adrian; Jeffrey W Tyner; Mary Mac Partlin; David J Anderson; Scott C Wise; Bryan D Smith; Peter A Petillo; Daniel L Flynn; Michael W N Deininger; Thomas O'Hare; Brian J Druker
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Cancer research 2011;71(9):3189-95.
2011: Thomas O'Hare; Michael W N Deininger; Christopher A Eide; Tim Clackson; Brian J Druker
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(2):212-21.
2010: Daniel W Sherbenou; Oliver Hantschel; Ines Kaupe; Stephanie Willis; Thomas Bumm; Lalita P Turaga; Thoralf Lange; Kim-Hien Dao; Richard D Press; Brian J Druker; Giulio Superti-Furga; Michael W N Deininger
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Blood 2010;116(17):3278-85.
2010: Paul La Rosée; Michael W N Deininger
Resistance to imatinib: mutations and beyond.
Seminars in hematology 2010;47(4):335-43.
2010: Ji-Heui Seo; Lisa J Wood; Anupriya Agarwal; Thomas O'Hare; Collin R Elsea; Ian J Griswold; Michael W N Deininger; Akira Imamoto; Brian J Druker
A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.
Cancer research 2010;70(18):7325-35.
2010: Jeffrey W Tyner; Luke B Fletcher; Ellen Q Wang; Wayne F Yang; Michael L Rutenberg-Schoenberg; Carol Beadling; Motomi Mori; Michael C Heinrich; Michael W N Deininger; Brian J Druker; Marc Loriaux
MET receptor sequence variants R970C and T992I lack transforming capacity.
Cancer research 2010;70(15):6233-7.
2010: Thomas Bumm; J Deininger; A H Newell; Helen Lawce; Susan B Olson; Michael J Mauro; Brian J Druker; Michael W N Deininger
Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.
Leukemia 2010;24(8):1525-8.
2010: Sandra A Bright; Giuseppe Campiani; Michael W N Deininger; Mark Lawler; D Clive Williams; Daniela M Zisterer
Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
Biochemical pharmacology 2010;80(1):31-8.
2010: Jeffrey W Tyner; Thomas G Bumm; Jutta Deininger; Lisa J Wood; Karl J Aichberger; Marc Loriaux; Brian J Druker; Christopher J Burns; Emmanuelle Fantino; Michael W N Deininger
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Blood 2010;115(25):5232-40.
2010: Elie Traer; Michael W N Deininger
How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2010;10 Suppl 1():S20-6.
2010: S A Bright; A M McElligott; J W O'Connell; L O'Connor; P Carroll; G Campiani; Michael W N Deininger; Eibhlin Conneally; Mark Lawler; D C Williams; Daniela M Zisterer
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.
British journal of cancer 2010;102(10):1474-82.
2010: Michael W N Deininger
Chronic myelogenous leukemia therapy beyond imatinib.
Clinical advances in hematology & oncology : H&O 2010;8(3):178-80.
2010: Shannon McWeeney; Lucy C Pemberton; Marc Loriaux; Kristina Vartanian; Stephanie G Willis; Gregory Yochum; Beth Wilmot; Yaron Turpaz; Raji Pillai; Brian J Druker; Jennifer L Snead; Mary MacPartlin; Stephen G O'Brien; Junia V Melo; Thoralf Lange; Christina A Harrington; Michael W N Deininger
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.
Blood 2010;115(2):315-25.
2010: S Demehri; T O'Hare; C A Eide; C A Smith; J W Tyner; Brian J Druker; Michael W N Deininger
The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis.
Leukemia 2010;24(1):226-9.
2009: Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael W N Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Andrew Lamb; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(35):6041-51.
2009: Thomas O'Hare; William C Shakespeare; Xiaotian Zhu; Christopher A Eide; Victor M Rivera; Frank Wang; Lauren T Adrian; Tianjun Zhou; Wei-Sheng Huang; Qihong Xu; Chester A Metcalf; Jeffrey W Tyner; Marc Loriaux; Amie S Corbin; Scott Wardwell; Yaoyu Ning; Jeffrey A Keats; Yihan Wang; Raji Sundaramoorthi; Mathew Thomas; Dong Zhou; Joseph Snodgrass; Lois Commodore; Tomi K Sawyer; David C Dalgarno; Michael W N Deininger; Brian J Druker; Tim Clackson
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Cancer cell 2009;16(5):401-12.
2009: Jennifer L Snead; Thomas O'Hare; Lauren T Adrian; Christopher A Eide; Thoralf Lange; Brian J Druker; Michael W N Deininger
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Blood 2009;114(16):3459-63.
2009: Karl J Aichberger; Angela G Fleischman; Michael W N Deininger
Same mutation, different allele.
Blood 2009;114(14):2853-4.
2009: Richard D Press; Stephanie G Willis; Jennifer Laudadio; Michael J Mauro; Michael W N Deininger
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
Blood 2009;114(13):2598-605.
2009: Michael J Mauro; Michael W N Deininger
Management of drug toxicities in chronic myeloid leukaemia.
Best practice & research. Clinical haematology 2009;22(3):409-29.
2009: Jeffrey W Tyner; M L Rutenberg-Schoenberg; H Erickson; S G Willis; Thomas O'Hare; Michael W N Deininger; Brian J Druker; Marc Loriaux
Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation.
Leukemia 2009;23(7):1345-8.
2009: Jeffrey W Tyner; Michael W N Deininger; Marc Loriaux; Bill Hoon Chang; Jason R Gotlib; Stephanie G Willis; Heidi Erickson; Tibor J Kovacsovics; Thomas O'Hare; Michael C Heinrich; Brian J Druker
RNAi screen for rapid therapeutic target identification in leukemia patients.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(21):8695-700.
2009: Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc Loriaux
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
Blood 2009;113(8):1749-55.
2009: V G Oehler; J Qin; R Ramakrishnan; G Facer; S Ananthnarayan; C Cummings; Michael W N Deininger; N Shah; F McCormick; S Willis; A Daridon; M Unger; J P Radich
Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.
Leukemia 2009;23(2):396-9.
2009: Jeffrey W Tyner; Marc Loriaux; H Erickson; C A Eide; J Deininger; Mary MacPartlin; S G Willis; Thoralf Lange; Brian J Druker; Tibor J Kovacsovics; Richard T Maziarz; N Gattermann; Michael W N Deininger
High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia.
Leukemia 2009;23(2):406-9.
2009: Kara J Johnson; Ian J Griswold; Thomas O'Hare; Amie S Corbin; Marc Loriaux; Michael W N Deininger; Brian J Druker
A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.
PloS one 2009;4(10):e7439.
2009: Clara I Aceves-Luquero; Anupriya Agarwal; Juan L Callejas-Valera; Laura Arias-González; Azucena Esparís-Ogando; Luis del Peso Ovalle; Itxaso Bellón-Echeverria; Miguel A de la Cruz-Morcillo; Eva M Galán Moya; Inmaculada Moreno Gimeno; Juan C Gómez; Michael W N Deininger; Atanasio Pandiella; Ricardo Sánchez Prieto
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
PloS one 2009;4(7):e6124.
2008: Thomas O'Hare; Michael W N Deininger
Toward a cure for chronic myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(24):7971-4.
2008: O Pelz-Ackermann; Michael Cross; H Pfeifer; Michael W N Deininger; S-Y Wang; Haifa-Kathrin Al-Ali; Dietger Niederwieser; Thoralf Lange
Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR.
Leukemia 2008;22(12):2288-91.
2008: A Agarwal; C A Eide; A Harlow; A S Corbin; Michael J Mauro; Brian J Druker; Christopher L Corless; Michael C Heinrich; Michael W N Deininger
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
Leukemia 2008;22(12):2269-72.
2008: Anupriya Agarwal; Thomas Bumm; Amie S Corbin; Thomas O'Hare; Marc Loriaux; Jonathan VanDyke; Stephanie G Willis; Jutta Deininger; Keiichi I Nakayama; Brian J Druker; Michael W N Deininger
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Blood 2008;112(5):1960-70.
2008: Thomas O'Hare; Christopher A Eide; Michael W N Deininger
Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia.
Journal of the National Cancer Institute 2008;100(13):908-9.
2008: Michael W N Deininger
Nilotinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4027-31.
2008: Mary MacPartlin; A M Smith; Brian J Druker; L A Honigberg; Michael W N Deininger
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
Leukemia 2008;22(7):1354-60.
2008: Neil P Shah; Hagop M Kantarjian; Dong-Wook Kim; Delphine Réa; Pedro E Dorlhiac-Llacer; Jorge H Milone; Jorge Vela-Ojeda; Richard T Silver; H Jean Khoury; Aude Charbonnier; Nina Khoroshko; Ronald L Paquette; Michael W N Deininger; Robert H Collins; Irma Otero; Timothy Hughes; Eric Bleickardt; Lewis Strauss; Stephen Francis; Andreas Hochhaus
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(19):3204-12.
2008: Thomas O'Hare; Christopher A Eide; Michael W N Deininger
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
Expert opinion on investigational drugs 2008;17(6):865-78.
2008: A Hochhaus; M Baccarani; Michael W N Deininger; J F Apperley; J H Lipton; S L Goldberg; S Corm; N P Shah; F Cervantes; R T Silver; Dietger Niederwieser; Richard M Stone; H Dombret; R A Larson; L Roy; T Hughes; M C Müller; R Ezzeddine; A M Countouriotis; H M Kantarjian
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Leukemia 2008;22(6):1200-6.
2008: Daniel W Sherbenou; O Hantschel; L Turaga; I Kaupe; S Willis; Thomas Bumm; Richard D Press; G Superti-Furga; Brian J Druker; Michael W N Deininger
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
Leukemia 2008;22(6):1184-90.
2008: Marc Loriaux; Ross Levine; Jeffrey W Tyner; Stefan Fröhling; Claudia Scholl; Eric P Stoffregen; Gerlinde Wernig; Heidi Erickson; Christopher A Eide; Roland Berger; Olivier A Bernard; James D Griffin; Richard M Stone; Benjamin Lee; Matthew Meyerson; Michael C Heinrich; Michael W N Deininger; D Gary Gilliland; Brian J Druker
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.
Blood 2008;111(9):4788-96.
2008: Thomas O'Hare; Christopher A Eide; Jeffrey W Tyner; Amie S Corbin; Matthew Wong; Sean Buchanan; Kevin Holme; Katayoun A Jessen; Crystal Tang; Hal A Lewis; Richard D Romero; Stephen K Burley; Michael W N Deininger
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(14):5507-12.
2008: Peter Valent; Michael W N Deininger
Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.
Leukemia & lymphoma 2008;49(4):604-9.
2008: Jennifer L Snead; Thomas O'Hare; Christopher A Eide; Michael W N Deininger
New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?
Clinical lymphoma & myeloma 2008;8 Suppl 3():S107-17.
2008: Michael W N Deininger
Resistance and relapse with imatinib in CML: causes and consequences.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6 Suppl 2():S11-S21.
2008: Jennifer Laudadio; Michael W N Deininger; Michael J Mauro; Brian J Druker; Richard D Press
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.
The Journal of molecular diagnostics : JMD 2008;10(2):177-80.
2008: Jeffrey W Tyner; Denise K Walters; Stephanie G Willis; Mary Luttropp; Jason Oost; Marc Loriaux; Heidi Erickson; Amie S Corbin; Thomas O'Hare; Michael C Heinrich; Michael W N Deininger; Brian J Druker
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.
Blood 2008;111(4):2238-45.
2008: Francis Giles; Daniel J DeAngelo; Michele Baccarani; Michael W N Deininger; françois guilhot; Timothy Hughes; Michael J Mauro; Jerald Radich; Oliver G Ottmann; Jorge Cortes
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Seminars in oncology 2008;35(1 Suppl 1):S1-17; quiz S18-20.
2008: Valentina Nardi; T Raz; X Cao; Catherine J Wu; Richard M Stone; J Cortes; Michael W N Deininger; G Church; J Zhu; George Q Daley
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Oncogene 2008;27(6):775-82.
2008: Michael W N Deininger
Milestones and monitoring in patients with CML treated with imatinib.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2008;():419-26.
2008: Michael W N Deininger
Chronic myeloid leukemia: an historical perspective.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2008;():418.
2007: Stefan Fröhling; Claudia Scholl; Ross Levine; Marc Loriaux; Titus Boggon; Olivier A Bernard; Roland Berger; Hartmut Döhner; Konstanze Döhner; Benjamin L Ebert; Sewit Teckie; Todd R Golub; Jingrui Jiang; Marcus Schittenhelm; Benjamin H Lee; James D Griffin; Richard M Stone; Michael C Heinrich; Michael W N Deininger; Brian J Druker; D Gary Gilliland
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.
Cancer cell 2007;12(6):501-13.
2007: Fei Bao; Paula Polk; Mary L Nordberg; Diana M Veillon; Amanda Sun; Michael W N Deininger; David Murray; Borje S Andersson; Reinhold Munker
Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors.
Leukemia research 2007;31(11):1511-20.
2007: Richard D Press; Chad Galderisi; Rui Yang; Carole Rempfer; Stephanie G Willis; Michael J Mauro; Brian J Druker; Michael W N Deininger
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):6136-43.
2007: Michael W N Deininger; Jorge Cortes; Ron Paquette; Byung S Park; Andreas Hochhaus; Michele Baccarani; Richard M Stone; Thomas Fischer; Andrew Lamb; Dietger Niederwieser; Carlo Gambacorti-Passerini; Charlene So; Insa Gathmann; John M Goldman; B Douglas Smith; Brian J Druker; françois guilhot
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Cancer 2007;110(7):1509-19.
2007: Thomas O'Hare; Christopher A Eide; Michael W N Deininger
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
Blood 2007;110(7):2242-9.
2007: Carolyn Blasdel; Merrill J Egorin; Theodore F Lagattuta; Brian J Druker; Michael W N Deininger
Therapeutic drug monitoring in CML patients on imatinib.
Blood 2007;110(5):1699-701; author reply 1701.
2007: Michael W N Deininger
Optimizing therapy of chronic myeloid leukemia.
Experimental hematology 2007;35(4 Suppl 1):144-54.
2007: Thomas O'Hare; Christopher A Eide; Michael W N Deininger
Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia.
Clinical lymphoma & myeloma 2007;7 Suppl 3():S120-30.
2007: Daniel W Sherbenou; Matthew Wong; A Humayun; Laura McGreevey; Patina Harrell; R Yang; Michael J Mauro; Michael C Heinrich; Richard D Press; Brian J Druker; Michael W N Deininger
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.
Leukemia 2007;21(3):489-93.
2006: Brian J Druker; françois guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
The New England journal of medicine 2006;355(23):2408-17.
2006: Thomas Bumm; Collin Elsea; Amie S Corbin; Marc Loriaux; Daniel W Sherbenou; Lisa J Wood; Jutta Deininger; Richard T Silver; Brian J Druker; Michael W N Deininger
Characterization of murine JAK2V617F-positive myeloproliferative disease.
Cancer research 2006;66(23):11156-65.
2006: Paul La Rosée; Taiping Jia; Shadmehr Demehri; Nicolai Härtel; Peter de Vries; Lynn Bonham; David Hollenback; Jack W Singer; Junia V Melo; Brian J Druker; Michael W N Deininger
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6540-6.
2006: Heather Bradeen; Christopher A Eide; Thomas O'Hare; Kara J Johnson; Stephanie G Willis; Francis Y Lee; Brian J Druker; Michael W N Deininger
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.
Blood 2006;108(7):2332-8.
2006: Michele Baccarani; Giuseppe Saglio; John Goldman; Andreas Hochhaus; Bengt Simonsson; Frederick Appelbaum; Jane Apperley; Francisco Cervantes; Jorge Cortes; Michael W N Deininger; Alois Gratwohl; françois guilhot; Mary Horowitz; Timothy Hughes; Andrew Lamb; Richard Larson; Dietger Niederwieser; Richard Silver; Rüdiger Hehlmann
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Blood 2006;108(6):1809-20.
2006: Denise K Walters; Valerie L Goss; Eric P Stoffregen; Ting-Lei Gu; Kimberly Lee; Julie Nardone; Laura McGreevey; Michael C Heinrich; Michael W N Deininger; Roberto D Polakiewicz; Brian J Druker
Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes.
Leukemia research 2006;30(9):1097-104.
2006: Ian J Griswold; Mary MacPartlin; Thomas Bumm; Valerie L Goss; Thomas O'Hare; Kimberly A Lee; Amie S Corbin; Eric P Stoffregen; Caitlyn Smith; Kara Johnson; Erika M Moseson; Lisa J Wood; Roberto D Polakiewicz; Brian J Druker; Michael W N Deininger
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Molecular and cellular biology 2006;26(16):6082-93.
2006: Denise K Walters; Thomas Mercher; Ting-Lei Gu; Thomas O'Hare; Jeffrey W Tyner; Marc Loriaux; Valerie L Goss; Kimberly A Lee; Christopher A Eide; Matthew Wong; Eric P Stoffregen; Laura McGreevey; Julie Nardone; Sandra A Moore; John Crispino; Titus Boggon; Michael C Heinrich; Michael W N Deininger; Roberto D Polakiewicz; D Gary Gilliland; Brian J Druker
Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Cancer cell 2006;10(1):65-75.
2006: Timothy Hughes; Michael W N Deininger; Andreas Hochhaus; Susan Branford; Jerald P Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; giovanni martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Blood 2006;108(1):28-37.
2006: Richard D Press; Zac Love; Ashlie A Tronnes; Rui Yang; Thuan Tran; Solange Mongoue-Tchokote; Motomi Mori; Michael J Mauro; Michael W N Deininger; Brian J Druker
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
Blood 2006;107(11):4250-6.
2006: Michael W N Deininger; Michael Schleuning; Hilde Greinix; Herbert G Sayer; Thomas Fischer; Jesus Martinez; Richard T Maziarz; Eduardo Olavarria; Leo Verdonck; Kerstin Schaefer; Conxa Boqué; Edgar Faber; Arnon Nagler; Enrico Pogliani; Nigel Russell; Liisa Volin; Urs Schanz; Gottfried Doelken; Michael Kiehl; Axel A Fauser; Brian J Druker; Anna Sureda; Simona Iacobelli; Ronald Brand; Rainer Krahl; Thoralf Lange; Andreas Hochhaus; Alois Gratwohl; Hans Kolb; Dietger Niederwieser
The effect of prior exposure to imatinib on transplant-related mortality.
Haematologica 2006;91(4):452-9.
2006: Shadmehr Demehri; Amie S Corbin; Marc Loriaux; Brian J Druker; Michael W N Deininger
Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia.
Experimental hematology 2006;34(3):284-8.
2006: Michael J Mauro; Michael W N Deininger
Chronic myeloid leukemia in 2006: a perspective.
Haematologica 2006;91(2):152.
2006: Marcus Schittenhelm; Sharon Shiraga; Arin Schroeder; Amie S Corbin; Diana Griffith; Francis Y Lee; Carsten Bokemeyer; Michael W N Deininger; Brian J Druker; Michael C Heinrich
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Cancer research 2006;66(1):473-81.
2005: Thoralf Lange; Byung S Park; Stephanie G Willis; Michael W N Deininger
BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?
Cell cycle (Georgetown, Tex.) 2005;4(12):1761-6.
2005: Ross Levine; Marc Loriaux; Brian J P Huntly; Mignon L Loh; Miroslav Beran; Eric P Stoffregen; Roland Berger; Jennifer J Clark; Stephanie G Willis; Kim T Nguyen; Nikki J Flores; Elihu Estey; Norbert Gattermann; Scott A Armstrong; A Thomas Look; James D Griffin; Olivier A Bernard; Michael C Heinrich; D Gary Gilliland; Brian J Druker; Michael W N Deininger
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Blood 2005;106(10):3377-9.
2005: Michael W N Deininger
Resistance to imatinib: mechanisms and management.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(6):757-68.
2005: C Chuah; David J Barnes; M Kwok; Amie S Corbin; Michael W N Deininger; Brian J Druker; Junia V Melo
Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.
Leukemia 2005;19(11):1896-904.
2005: Lucy C Crossman; Thomas O'Hare; Thoralf Lange; Stephanie G Willis; Eric P Stoffregen; Amie S Corbin; Stephen G O'Brien; Michael C Heinrich; Brian J Druker; P G Middleton; Michael W N Deininger
A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib.
Leukemia 2005;19(11):1859-62.
2005: Karl J Aichberger; Matthias Mayerhofer; Maria-Theresa Krauth; Anja Vales; Rudin Kondo; Sophia Derdak; Winfried F Pickl; Edgar Selzer; Michael W N Deininger; Brian J Druker; Christian Sillaber; Harald Esterbauer; Peter Valent
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Cancer research 2005;65(20):9436-44.
2005: Thomas O'Hare; Denise K Walters; Eric P Stoffregen; Daniel W Sherbenou; Michael C Heinrich; Michael W N Deininger; Brian J Druker
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6987-93.
2005: Stephanie G Willis; Thoralf Lange; Shadmehr Demehri; Sandra Otto; Lucy C Crossman; Dietger Niederwieser; Eric P Stoffregen; Shannon McWeeney; Ines Kovacs; Byung S Park; Brian J Druker; Michael W N Deininger
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.
Blood 2005;106(6):2128-37.
2005: Lucy C Crossman; Brian J Druker; Michael W N Deininger; Munir Pirmohamed; Lihui Wang; Richard E Clark
hOCT 1 and resistance to imatinib.
Blood 2005;106(3):1133-4; author reply 1134.
2005: Thoralf Lange; Thomas Bumm; M Mueller; S Otto; Haifa-Kathrin Al-Ali; L Grommisch; S Musiol; C Franke; Rainer Krahl; Dietger Niederwieser; Michael W N Deininger
Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation.
Leukemia 2005;19(7):1262-5.
2005: Amie S Corbin; Shadmehr Demehri; Ian J Griswold; Yihan Wang; Chester A Metcalf; Raji Sundaramoorthi; William C Shakespeare; Joseph Snodgrass; Scott Wardwell; David C Dalgarno; John D Iuliucci; Tomi K Sawyer; Michael C Heinrich; Brian J Druker; Michael W N Deininger
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
Blood 2005;106(1):227-34.
2005: Thomas O'Hare; Denise K Walters; Eric P Stoffregen; Taiping Jia; Paul W Manley; Jürgen Mestan; Sandra W Cowan-Jacob; Francis Y Lee; Michael C Heinrich; Michael W N Deininger; Brian J Druker
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Cancer research 2005;65(11):4500-5.
2005: Matthias Mayerhofer; Karl J Aichberger; Stefan Florian; Maria-Theresa Krauth; Alexander W Hauswirth; Sophia Derdak; Wolfgang R Sperr; Harald Esterbauer; Oswald Wagner; Christine Marosi; Winfried F Pickl; Michael W N Deininger; Ellen Weisberg; Brian J Druker; James D Griffin; Christian Sillaber; Peter Valent
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(8):960-2.
2005: Lucy C Crossman; Motomi Mori; Yi-Ching Hsieh; Thoralf Lange; Peter Paschka; Christina A Harrington; Knut Krohn; Dietger Niederwieser; Rüdiger Hehlmann; Andreas Hochhaus; Brian J Druker; Michael W N Deininger
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.
Haematologica 2005;90(4):459-64.
2005: Shadmehr Demehri; Peter Paschka; Beate Schultheis; Thoralf Lange; T Koizumi; T Sugimoto; S Branford; L C Lim; T Kegel; giovanni martinelli; Andreas Hochhaus; Brian J Druker; Michael W N Deininger
e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?
Leukemia 2005;19(4):681-4.
2005: Michael W N Deininger; Elisabeth Buchdunger; Brian J Druker
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Blood 2005;105(7):2640-53.
2005: Denise K Walters; Eric P Stoffregen; Michael C Heinrich; Michael W N Deininger; Brian J Druker
RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.
Blood 2005;105(7):2952-4.
2005: Michael W N Deininger; Tessa L Holyoake
Can we afford to let sleeping dogs lie?
Blood 2005;105(5):1840-1.
2005: Thomas O'Hare; Denise K Walters; Michael W N Deininger; Brian J Druker
AMN107: tightening the grip of imatinib.
Cancer cell 2005;7(2):117-9.
2005: Michael W N Deininger
Management of early stage disease.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2005;():174-82.
2004: Amie S Corbin; Ian J Griswold; Paul La Rosée; Kevin W H Yee; Michael C Heinrich; Corinne L Reimer; Brian J Druker; Michael W N Deininger
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
Blood 2004;104(12):3754-7.
2004: A H Grossmann; K S Kolibaba; Stephanie G Willis; Amie S Corbin; W S Langdon; Michael W N Deininger; Brian J Druker
Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl.
FEBS letters 2004;577(3):555-62.
2004: Marc Loriaux; Michael W N Deininger
Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib.
Leukemia & lymphoma 2004;45(11):2197-203.
2004: Ian J Griswold; Lei J Shen; Paul La Rosée; Shadmehr Demehri; Michael C Heinrich; Rita M Braziel; Laura McGreevey; Andrea Haley; Neill Giese; Brian J Druker; Michael W N Deininger
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.
Blood 2004;104(9):2912-8.
2004: Thomas O'Hare; Roy Pollock; Eric P Stoffregen; Jeffrey A Keats; Omar M Abdullah; Erika M Moseson; Victor M Rivera; Hao Tang; Chester A Metcalf; Regine S Bohacek; Yihan Wang; Raji Sundaramoorthi; William C Shakespeare; David C Dalgarno; Tim Clackson; Tomi K Sawyer; Michael W N Deininger; Brian J Druker
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
Blood 2004;104(8):2532-9.
2004: Thoralf Lange; Michael W N Deininger; Ronald Brand; Ute Hegenbart; Haifa-Kathrin Al-Ali; Rainer Krahl; W Poenisch; Lutz Uharek; Sabine Leiblein; Chiara Gentilini; Effie W Petersdorf; Rainer Storb; Dietger Niederwieser
BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
Leukemia 2004;18(9):1468-75.
2004: Richard T Silver; john bennett; Michael W N Deininger; Eric Feldman; Shahin Rafii; R L Silverstein; Lawrence Solberg; Jerry L Spivak
The second international congress on myeloproliferative and myelodysplastic syndromes.
Leukemia research 2004;28(9):979-85.
2004: Michael W N Deininger; Brian J Druker
SRCircumventing imatinib resistance.
Cancer cell 2004;6(2):108-10.
2004: Michael J Mauro; Marc Loriaux; Michael W N Deininger
Ph-positive and -negative myeloproliferative syndromes may co-exist.
Leukemia 2004;18(7):1305-7.
2004: Junia V Melo; Michael W N Deininger
Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
Hematology/oncology clinics of North America 2004;18(3):545-68, vii-viii.
2004: Michael W N Deininger
Src kinases in Ph+ lymphoblastic leukemia.
Nature genetics 2004;36(5):440-1.
2004: Michael W N Deininger; Laura McGreevey; S Willis; Troy Bainbridge; Brian J Druker; Michael C Heinrich
Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography.
Leukemia 2004;18(4):864-71.
2004: Michael W N Deininger
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Journal of cancer research and clinical oncology 2004;130(2):59-72.
2004: Thoralf Lange; Thomas Bumm; Sandra Otto; Haifa-Kathrin Al-Ali; Ines Kovacs; Daniela Krug; Thomas Köhler; Rainer Krahl; Dietger Niederwieser; Michael W N Deininger
Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
Haematologica 2004;89(1):49-57.
2004: Haifa-Kathrin Al-Ali; Michael C Heinrich; Thoralf Lange; Rainer Krahl; Matthias Mueller; Christel Müller; Dietger Niederwieser; Brian J Druker; Michael W N Deininger
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(1):55-60.
2004: Isabelle Gaston; Kara J Johnson; Tsukasa Oda; Arun Bhat; Margaret Reis; Wallace Langdon; Lei Shen; Michael W N Deininger; Brian J Druker
Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl.
Experimental hematology 2004;32(1):113-21.
2004: Paul La Rosée; Kara Johnson; Amie S Corbin; Eric P Stoffregen; Erika M Moseson; Stephanie Willis; Michael J Mauro; Junia V Melo; Michael W N Deininger; Brian J Druker
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Blood 2004;103(1):208-15.
2003: Daniela M Dinulescu; Lisa J Wood; Lei Shen; Marc Loriaux; Christopher L Corless; Alec W Gross; Ruibao Ren; Michael W N Deininger; Brian J Druker
c-CBL is not required for leukemia induction by Bcr-Abl in mice.
Oncogene 2003;22(55):8852-60.
2003: Martin C Müller; Norbert Gattermann; Tanja Lahaye; Michael W N Deininger; A Berndt; Stefan Fruehauf; Andreas Neubauer; Thomas Fischer; Dieter K Hossfeld; Folker Schneller; S W Krause; Christoph Nerl; Herbert G Sayer; Oliver G Ottmann; C Waller; Walter Aulitzky; Philipp le Coutre; Mathias Freund; Kirsten Merx; Peter Paschka; Heiko König; Sebastian Kreil; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Leukemia 2003;17(12):2392-400.
2003: Alex J Tipping; Michael W N Deininger; John M Goldman; Junia V Melo
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
Experimental hematology 2003;31(11):1073-80.
2003: Thoralf Lange; Dietger Niederwieser; Michael W N Deininger
Residual disease in chronic myeloid leukemia after induction of molecular remission.
The New England journal of medicine 2003;349(15):1483-4.
2003: Marcus Wiedmann; Florian Kreth; Jürgen Feisthammel; Michael W N Deininger; Joachim Mössner; Karel Caca
Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
Anti-cancer drugs 2003;14(9):751-60.
2003: U Reinhold; Evelin Hennig; Sabine Leiblein; Dietger Niederwieser; Michael W N Deininger
FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib.
Leukemia 2003;17(10):1925-9.
2003: Brian J P Huntly; françois guilhot; Alistair G Reid; George S Vassiliou; Evelin Hennig; Christina Franke; Jennie Byrne; Andre Brizard; Dietger Niederwieser; Julie Freeman-Edward; Gavin Cuthbert; Nick Bown; Richard E Clark; Elisabeth P Nacheva; Anthony R Green; Michael W N Deininger
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.
Blood 2003;102(6):2205-12.
2003: Eduardo Olavarria; O G Ottmann; Michael W N Deininger; R E Clark; G Bandini; J Byrne; J Lipton; A Vitek; Mauricette Michallet; Wolfgang Siegert; A Ullmann; Barbara Wassmann; Dietger Niederwieser; T Fischer
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Leukemia 2003;17(9):1707-12.
2003: Michael W N Deininger; Brian J Druker
Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Pharmacological reviews 2003;55(3):401-23.
2003: Mathias Rumpel; Thomas Friedrich; Michael W N Deininger
Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase.
Blood 2003;101(11):4641-3.
2003: Amie S Corbin; Paul La Rosée; Eric P Stoffregen; Brian J Druker; Michael W N Deininger
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.
Blood 2003;101(11):4611-4.
2003: Michael W N Deininger; Stephen G O'Brien; John M Ford; Brian J Druker
Practical management of patients with chronic myeloid leukemia receiving imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1637-47.
2003: Michael W N Deininger
Cytogenetic studies in patients on imatinib.
Seminars in hematology 2003;40(2 Suppl 2):50-5.
2003: Stephen G O'Brien; Michael W N Deininger
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Seminars in hematology 2003;40(2 Suppl 2):26-30.
2003: Thoralf Lange; Christine Günther; Thomas Köhler; Rainer Krahl; Scarlet Musiol; Sabine Leiblein; Haifa-Kathrin Al-Ali; Iris van Hoomissen; Dietger Niederwieser; Michael W N Deininger
High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.
Blood 2003;101(6):2152-5.
2003: Thomas Bumm; Christel Müller; Haifa-Kathrin Al-Ali; Knut Krohn; Patricia Shepherd; Erika Schmidt; Sabine Leiblein; Christina Franke; Evelin Hennig; Thomas Friedrich; Rainer Krahl; Dietger Niederwieser; Michael W N Deininger
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Blood 2003;101(5):1941-9.
2003: Dietger Niederwieser; Michael B Maris; Judith A Shizuru; Effie W Petersdorf; Ute Hegenbart; Brenda M Sandmaier; David G Maloney; Barry Storer; Thoralf Lange; Thomas R Chauncey; Michael W N Deininger; Wolfram Pönisch; Claudio Anasetti; Ann Woolfrey; Marie-Térèse Little; Karl G Blume; Peter A McSweeney; Rainer F Storb
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.
Blood 2003;101(4):1620-9.
2003: Paul La Rosée; Lei Shen; Eric P Stoffregen; Michael W N Deininger; Brian J Druker
No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).
The hematology journal : the official journal of the European Haematology Association / EHA 2003;4(6):413-9.
2002: Paul La Rosée; Amie S Corbin; Eric P Stoffregen; Michael W N Deininger; Brian J Druker
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
Cancer research 2002;62(24):7149-53.
2002: Oliver G Ottmann; Brian J Druker; Charles L Sawyers; John M Goldman; Josy Reiffers; Richard T Silver; Sante Tura; Thomas Fischer; Michael W N Deininger; Charles Alan Schiffer; Michele Baccarani; Alois Gratwohl; Andreas Hochhaus; Dieter Hoelzer; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Stephen G O'Brien
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Blood 2002;100(6):1965-71.
2002: Haifa-Kathrin Al-Ali; Sabine Leiblein; Ines Kovacs; Evelin Hennig; Dietger Niederwieser; Michael W N Deininger
CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall.
Blood 2002;100(3):1092-3.
2002: Christel Müller; Evelin Hennig; Christina Franke; Rainer Krahl; Sabine Leiblein; Dietger Niederwieser; Michael W N Deininger
The BCR/ABL-extra signal fluorescence in situ hybridization system reliably detects deletions upstream of the ABL locus: implications for reporting of results and followup of chronic myelogenous leukemia patients.
Cancer genetics and cytogenetics 2002;136(2):149-50.
2002: Brian J P Huntly; Anthony J Bench; Eric Delabesse; Alistair G Reid; Juan Li; Mike A Scott; Lynda Campbell; Jennie Byrne; Eleanor Pinto; Andre Brizard; Deitger Niedermeiser; Elisabeth P Nacheva; françois guilhot; Michael W N Deininger; Anthony R Green
Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.
Blood 2002;99(12):4547-53.
2002: Charles L Sawyers; Andreas Hochhaus; Eric Feldman; John M Goldman; Carole B Miller; Oliver G Ottmann; Charles Alan Schiffer; Moshe Talpaz; françois guilhot; Michael W N Deininger; Thomas Fischer; Steve G O'Brien; Richard M Stone; Carlo B Gambacorti-Passerini; Nigel H Russell; Jose J Reiffers; Thomas C Shea; Bernard Chapuis; Steven Coutre; Sante Tura; Enrica Morra; Richard A Larson; Alan Saven; Christian Peschel; Alois Gratwohl; Franco Mandelli; Monique Ben-Am; Insa Gathmann; Renaud Capdeville; Ronald L Paquette; Brian J Druker
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Blood 2002;99(10):3530-9.
2002: Alistair G Reid; Brian J P Huntly; Eveline Hennig; Dietger Niederwieser; Lynda J Campbell; Nick Bown; Nick Telford; Helen Walker; Colin Grace; Michael W N Deininger; Anthony R Green; Elisabeth P Nacheva
Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia.
Blood 2002;99(6):2274-5.
2002: Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; françois guilhot; Charles Alan Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002;99(6):1928-37.
2002: Michael W N Deininger; Dietger Niederwieser
[Molecular therapy of chronic myeloid leukemia--a new era in the treatment of malignant diseases].
Medizinische Klinik (Munich, Germany : 1983) 2002;97 Suppl 1():1.
2002: Thomas Köhler; C Schill; Michael W N Deininger; Rainer Krahl; Silke Borchert; Dirk Hasenclever; Sabine Leiblein; Oswald Wagner; Dietger Niederwieser
High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML).
Leukemia 2002;16(1):22-9.
2001: S A Vieira; Michael W N Deininger; A Sorour; Paul Sinclair; Letizia Foroni; John M Goldman; Junia V Melo
Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene.
Genes, chromosomes & cancer 2001;32(4):353-63.
2001: Michael W N Deininger; S A Vieira; Y Parada; Lolita Banerji; Eric W-F Lam; G Peters; François-Xavier Mahon; T Köhler; John M Goldman; Junia V Melo
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Cancer research 2001;61(21):8005-13.
2001: Michael W N Deininger; Wolfram Pönisch; Rainer Krahl; Sabine Leiblein; E Edel; Thoralf Lange; Friedrich Fiedler; Mathias Freund; Astrid Franke; Rita Pasold; Ullrich von Grünhagen; Michael Herold; Gottfried Dölken; F A Hoffmann; R Uhle; W Schultze; J Steglich; A Schwarzer; P Richter; C Winkelmann; Erika Kettner; K Dachselt; R Subert; E Schwalbe; J Doepper; Werner Helbig; Dietger Niederwieser
Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.
Bone marrow transplantation 2001;27(11):1125-32.
2000: Michael W N Deininger; J M Goldman; J V Melo
The molecular biology of chronic myeloid leukemia.
Blood 2000;96(10):3343-56.
2000: François-Xavier Mahon; Michael W N Deininger; Beate Schultheis; J Chabrol; J Reiffers; John M Goldman; Junia V Melo
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
Blood 2000;96(3):1070-9.
2000: Michael W N Deininger; T Lehmann; Rainer Krahl; Evelin Hennig; Christel Müller; Dietger Niederwieser
No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogenic transplantation for chronic myeloid leukemia.
Blood 2000;96(2):779-80.
2000: Stephen B Marley; Michael W N Deininger; R J Davidson; J M Goldman; Myrtle Y Gordon
The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia.
Experimental hematology 2000;28(5):551-7.
2000: Michael W N Deininger; S Vieira; R Mendiola; Beate Schultheis; John M Goldman; Junia V Melo
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Cancer research 2000;60(7):2049-55.
1998: J Gora-Tybor; Michael W N Deininger; John M Goldman; Junia V Melo
The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL.
British journal of haematology 1998;103(3):716-20.
1998: S Bose; Michael W N Deininger; J Gora-Tybor; John M Goldman; Junia V Melo
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.
Blood 1998;92(9):3362-7.
1998: Michael W N Deininger; John M Goldman
Chronic myeloid leukemia.
Current opinion in hematology 1998;5(4):302-8.
1998: Michael W N Deininger; S Bose; J Gora-Tybor; X H Yan; John M Goldman; Junia V Melo
Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation.
Cancer research 1998;58(3):421-5.
1997: Michael W N Deininger; John M Goldman; N Lydon; Junia V Melo
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.
Blood 1997;90(9):3691-8.
1993: J P da Silva; J H Vila; M M Cascudo; J F Baumgratz; T Gauze Filho; Michael W N Deininger; N B Carvalho; A Tangari Júnior; W F Leite; M Wafae Filho
[The heart-lung transplant. Initial clinical experience].
Revista portuguesa de cardiologia : orgão oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 1993;12(1):9, 51-5.